Comparative Pharmacology
Head-to-head clinical analysis: RAUWILOID versus RAUWOLFIA SERPENTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUWILOID versus RAUWOLFIA SERPENTINA.
RAUWILOID vs RAUWOLFIA SERPENTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Category C
Category C
Antihypertensive
Antihypertensive